

The efficacy and safety of a novel PD-1/CTLA-4 bispecific antibody cadonilimab (AK104) in advanced non-small cell lung cancer: A multicenter retrospective observational study

Hongxin Li¹ | Wen Zhao²  | Chengming Li³ | Hongchang Shen⁴ | Meiyi Li⁵ | Chengjun Wang² | Chunyan Han^{6,7}  | Cuihua Yi² | Jun Wang^{8,9}  | Xue Meng³ | Lian Liu² | Shuwen Yu^{10,11} | Jisheng Li² 

¹School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, China

²Department of Medical Oncology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China

³Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China

⁴Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China

⁵Clinical Trial Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China

⁶Department of Oncology, Shandong Provincial Third Hospital, Shandong University, Jinan, China

⁷Department of Radiotherapy, The Third Affiliated Hospital of Shandong First Medical University (Affiliated Hospital of Shandong Academy of Medical Sciences), Jinan, China

⁸Department of Oncology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, China

⁹Shandong Lung Cancer Institute, Jinan, China

¹⁰Department of Pharmacy, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China

¹¹Clinical Trial Center, NMPA Key Laboratory for Clinical Research and Evaluation of Innovative Drugs, Shandong University, Jinan, China

Correspondence

Jisheng Li, No. 107 Wenhua West Road, Jinan, Shandong Province 250012, China.

Email: lijisheng@sdu.edu.cn

Funding information

National Natural Science Foundation of China, Grant/Award Number: 82303749; Clinical Research Fund of Shandong Medical Association-Qilu Special Project, Grant/Award Number: YXH2022ZX02212; Beijing Science and Technology Innovation Medical Development Foundation, Grant/Award Number: KC2023JX0186PZ091; Hui Lan Public Welfare Foundation Project, Grant/Award Number: HLZY20231128001; Natural Science Foundation of Shandong Province, Grant/Award Number: ZR2020LZL018

Abstract

Background: For patients with advanced non-small cell lung cancer (NSCLC) who have received frontline immunotherapy, subsequent treatment options are limited. As the first dual programmed cell death-1 (PD-1)/cytotoxic T lymphocyte-associated antigen-4 bispecific antibody approved globally, cadonilimab demonstrated potential antitumor activity in advanced NSCLC patients resistant to anti-PD-1/PD-L1 antibodies.

Methods: We retrospectively collected efficacy and safety data from advanced NSCLC patients treated with cadonilimab-based regimens in later therapy lines.

Results: A total of 41 advanced NSCLC patients refractory to anti-PD-1/PD-L1 therapy were enrolled. More than half of the patients received cadonilimab-based regimen as a fourth or later line of treatment. At the data cutoff date, treatment efficacy could be evaluated in 23 patients. One patient (4.3%) achieved partial response, eight patients (34.8%) experienced stable disease, and 14 patients (60.9%) progressed. The objective response rate and disease control rate were 4.3% and 39.1%, respectively. The median progression-free survival for all evaluated patients was 108.0 days. Due to the short follow-up period, the median overall survival has not yet been reached. Treatment-related adverse events (TRAEs) and immune-related AEs occurred in 63.4% and 22% patients, respectively. The most common TRAEs included gamma-

Hongxin Li and Wen Zhao contributed equally to this work. They are listed as the co-first authors.

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial-NoDerivs](https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2024 The Author(s). *Thoracic Cancer* published by John Wiley & Sons Australia, Ltd.

glutamyl transferase elevation (17.1%), coughing (14.6%), and fatigue (12.2%). Five patients (12.2%) experienced grade ≥ 3 TRAEs.

Conclusions: In this heavily pretreated cohort of advanced NSCLC patients, cadonilimab-based regimens showed moderate antitumor efficacy with a generally tolerable and manageable safety profile. However, more evidence is needed to support the administration of cadonilimab in NSCLC patients refractory to previous anti-PD-1/PD-L1 therapy.

KEY WORDS

bispecific antibody, cadonilimab, CTLA-4, non-small cell lung cancer, PD-1

INTRODUCTION

Worldwide, lung cancer remains the leading cause of cancer-related deaths, with over 1.2 million deaths expected globally in 2023.¹ Non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancer cases, and its treatment has undergone significant changes in recent years.² For the majority of NSCLC patients without an identifiable targeted therapy option, chemotherapy has been the mainstay for more than 40 years, with a median overall survival (OS) of less than 24 months for patients at advanced stages.³ Immune checkpoint inhibitors (ICIs) targeting programmed cell death-1 (PD-1), programmed cell death ligand-1 (PD-L1), and cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) have revolutionized the treatment of solid cancer including NSCLC. In 2017, the addition of pembrolizumab (anti-PD-1) to platinum-based frontline chemotherapy provided a significant OS benefit in advanced NSCLC and heralded the age of immunochemotherapy combination treatment.^{4,5} Recent studies have shown that ICI combination regimens also improve survival in patients with driver mutations progressing from targeted therapy.⁶ However, for patients who experienced disease progression after anti-PD-1/L1 therapy, treatment options are limited, and there is still no standard of care.

Preclinical studies have shown that co-inhibition of PD-1 and CTLA-4 synergistically transformed the tumor immune microenvironment into an antitumor phenotype.⁷ Clinical evidence suggested that CTLA-4 inhibitor combined with PD-1 or PD-L1 inhibitors had complementary action.^{8,9} As the world's first approved dual-specific ICI, cadonilimab (AK104) simultaneously blocks the immunosuppressive response of PD-1 and CTLA-4 signaling pathways, exerting synergistic antitumor efficacy.¹⁰ On June 29, 2022, cadonilimab received approval in China for the treatment of recurrent or metastatic cervical cancer that had progressed following platinum-based chemotherapy.¹¹ In a phase Ib/II trial, cadonilimab in combination with anlotinib achieved an objective response rate (ORR) of 62.5% and disease control rate (DCR) of 100% in eight evaluable advanced treatment-naïve NSCLC patients.¹² And the ORR reached 80% in a subgroup of five patients with nonsquamous NSCLC. Besides, this combination demonstrated a favorable safety profile in advanced NSCLC patients.¹²

However, it remains unclear whether advanced NSCLC patients who have progressed after frontline immunochemotherapy could benefit from cadonilimab therapy, and immune-related adverse events (irAEs) associated with cadonilimab in real-world settings also need further clarification. The current retrospective study thus aims to evaluate the efficacy and safety of cadonilimab in heavily pretreated advanced NSCLC patients.

METHODS

Patients and ethnic statement

This retrospective study was conducted in three cancer centers in Shandong Province, China, to investigate the efficacy and safety of cadonilimab in patients with advanced NSCLC. The inclusion criteria were (i) confirmed stage IV or recurrent NSCLC treated with cadonilimab or cadonilimab-based regimens and (ii) at least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. The exclusion criteria were (i) radiation therapy or other local treatments within 4 weeks prior to receiving cadonilimab for the target lesions used for assessing efficacy and (ii) long-term treatment with corticosteroids or immunosuppressants required due to accompanying diseases. Cadonilimab was administered intravenously at a dose of 6 mg/kg approximately every 2 weeks, until disease progression or the appearance of intolerable severe toxicity. The dosage and administration of other drugs were determined according to their specific instructions. Patients who were lost to follow-up but had records of adverse events were also analyzed for the safety profile. In total, 59 patients treated with cadonilimab were screened, and finally, 41 patients were enrolled for subsequent analysis.

This study complied with the Ethical Guidelines for Medical and Health Research Involving Human Subjects (KYLL-202309-062). The study protocol received approval from the Ethical Review Boards and Institutional Review Boards of all participating institutions. In China, cadonilimab has been officially approved for the treatment of patients with recurrent or metastatic cervical cancer who have experienced disease progression following platinum-based chemotherapy. The utilization of cadonilimab in our study was considered as an off-label application. Physicians

obtained informed consent from patients prior to prescribing cdonilimab. Given the retrospective nature of our study, further informed consent for the analysis was not required, and the exposure of personal information was strictly avoided.

Data collection

The following information was retrospectively collected through electronic medical records: (i) demographic information: age, sex, body mass index (BMI), smoking history, and Eastern Cooperative Oncology Group performance status (ECOG PS) score; (ii) disease information: stage, histological type, PD-L1 expression status (tumor cell proportion score [TPS]), genetic mutations, metastatic sites, and treatment history; (iii) efficacy information: DCR, ORR, PFS, and OS; (iv) TRAEs: hematological toxicity, hypertension, hand-foot skin reactions, liver function damage, thyroid function abnormalities, decreased appetite, and rash.

Outcome assessments and endpoints

Treatment response was evaluated according to RECIST version 1.1 based on CT imaging. Adverse events during cdonilimab treatment were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The primary endpoints were ORR, DCR, PFS, and safety; secondary endpoints included OS. The ORR was defined as the percentage of patients exhibiting either a complete or partial response to treatment, while the DCR was defined as the percentage of patients with a complete response, partial response, or stable disease. PFS and OS were assessed from the date of initial administration of cdonilimab. PFS was followed up until the first occurrence of tumor progression or death from any cause, whichever occurred first. OS was recorded until death from any cause or censored at the date of the latest available survival information.

Statistical analysis

All statistical analyses in this study were performed using SPSS version 27 (IBM, Chicago, IL, USA) and GraphPad Prism version 9.5.1 (San Diego, CA, USA). Demographic and clinical characteristics, as well as the incidence of adverse events, were summarized using descriptive statistics. Intergroup comparisons of DCR were conducted using the Pearson chi-squared test or Fisher's exact test to calculate 95% confidence intervals (CIs). The Kaplan-Meier method was used to estimate the median PFS and OS with 95% CIs. The median PFS between different subgroups was compared using the log-rank test at a 5% significance level. Hazard

ratios and 95% CIs for different treatment strategies and clinicopathological characteristics were computed using the univariate Cox proportional hazards model. Variables with a *p* value of less than 0.05 (considered statistically significant) in the univariate analysis were included in the multivariate Cox proportional hazards analysis.

RESULTS

Patient characteristics

As shown in Figure 1, a total of 59 patients treated with cdonilimab were screened. Forty-one patients with advanced NSCLC meeting the study criteria were included for subsequent analysis, of which 23 patients could be evaluated for therapeutic efficacy.

Demographics, clinicopathological characteristics, and treatment information are presented in Table 1. The median age at diagnosis was 58 years old (range 35–73), and 28 patients (68.3%) were male. Notably, most patients with NSCLC had an ECOG-PS score of 0 or 1 (92.7%) at the start of the treatment, whereas the remaining 7.3% had an ECOG-PS score of 2. Seventeen patients (41.5%) had a history of smoking. The proportion of adenocarcinoma and squamous cell carcinoma was 63.4% and 36.6%, respectively. PD-L1 TPS was <1% in 29.3% of patients, ≥1% in 24.4% of patients, and unknown in 46.3% of patients. Regarding driver gene mutations, 14 (34.1%) patients had *EGFR* mutation, and 2 (4.9%) patients had *ALK* mutation. Nine patients (22%) did not undergo detection of driver gene mutation, and all of them were diagnosed with advanced lung squamous cell carcinoma (LUSC). The proportion of brain metastasis, bone metastasis, liver metastasis, and adrenal glands metastasis was 41.5%, 51.2%, 31.7%, and 17.1%, respectively.

Thirty-eight patients (92.7%) have previously been treated with anti-PD-1/PD-L1 antibodies, and cdonilimab-containing regimens were given as third or later-line treatment in most (90.2%) cases. Of patients, 12.2% received cdonilimab as a single-agent treatment, while 31.7%, 29.3%, and 26.8% of patients received cdonilimab in combination with chemotherapy, anlotinib, and other antiangiogenic agents, respectively.

Treatment outcomes

The median follow-up time was 135 days (range 16–406 days). By August 29, 2023, 23 patients could be evaluated for treatment efficacy. The ORR and DCR were 4.3% and 39.1%, respectively. Specifically, one patient (4.3%) achieved a PR, eight patients (34.8%) achieved SD, and 14 patients (60.9%) experienced PD (Figure 2a). The DCR for patients treated with cdonilimab as a single agent, cdonilimab combined with chemotherapy, cdonilimab




FIGURE 1 Flowchart of patient selection.

combined with anlotinib, and cadonilimab combined with other antiangiogenic agents were 66.7%, 33.3%, 60%, and 22.2%, respectively. Patients treated with cadonilimab and antiangiogenic agents showed a lower DCR than those treated with cadonilimab-based regimens that did not include any antiangiogenic agents (35.7% vs. 44.4%, $p = 0.505$) (Figure 2b). Patients with LUSC achieved a higher DCR than those with LUAD (70% vs. 15.4%, $p = 0.012$) (Figure 2c). The DCR divided by PD-L1 expression is presented in Figure 2d. A relatively lower DCR was observed in patients carrying driver gene mutations than in those with wild-type driver genes (14.3% vs. 54.5%, $p = 0.08$) (Figure 2e). Patients with two or more metastatic sites achieved a DCR of 25%, while those with only one metastatic site showed a DCR as high as 54.5% ($p = 0.154$) (Figure 2f).

Due to the short follow-up period, median OS has not been reached yet (Figure 3a). The median PFS of all evaluated patients was 108.0 days (95% CI 62.3–153.7) (Figure 3b). There was no significant difference in the PFS according to PD-L1 expression groups (TPS $\geq 1\%$ [95 days] vs. TP <1% [129 days], $p = 0.4725$; Figure 4a), nor based on

the number of metastasis sites (<2 [124 days] vs. ≥ 2 [57 days], $p = 0.23$; Figure 4b). The median PFS was 104 days in LUAD patients, while the median PFS was not reached in LUSC patients ($p = 0.0726$, Figure 5a). Considering driver gene mutation status, patients with driver gene mutation showed shorter PFS than those with wild-type driver genes when treated with cadonilimab (57 vs. 129 days, $p = 0.0571$, Figure 5b). Additionally, there was no significant difference in PFS between LUAD patients with wild-type driver genes and LUSC patients ($p = 0.4843$, Figure 5c).

The only patient who achieved a PR is presented here (Figure 6). This male patient was diagnosed with LUSC. His disease stage at diagnosis was cT4N0M0, IIIA, based on thoracic CT, brain MRI, and PET-CT results. No driver gene mutation was detected by a 51-gene high-throughput sequencing. After five cycles of albumin-bound paclitaxel and nedaplatin treatment, he achieved stable disease, with the primary lesion in the left lung slightly enlarging. He underwent high-throughput sequencing again, which showed an EGFR 19del mutation with a 0.56% mutation allele frequency and a PD-L1 TPS of 3% by SP263 antibody. He

TABLE 1 Patient demographics and baseline characteristics.

Characteristics, N (%)	Treatment modality of cadonilimab				All patients
	Single agent	Combined with chemotherapy	Combined with anlotinib	Combined with other antiangiogenic agents	
Patients	5 (12.2)	13 (31.7)	12 (29.3)	11 (26.8)	41 (100)
Male	2 (7.1)	10 (35.7)	9 (32.1)	7 (25)	28 (68.3)
Female	3 (23.1)	3 (23.1)	3 (23.1)	4 (30.8)	13 (31.7)
Age (years), median (range)	63 (35–70)	59 (38–73)	56 (40–71)	57 (40–69)	58 (35–73)
Smoking history					
Ever	1 (5.9)	7 (41.2)	3 (17.6)	6 (35.3)	17 (41.5)
Never	4 (16.7)	6 (25)	9 (37.5)	5 (20.8)	24 (58.5)
Histological type					
Squamous cell carcinoma	3 (20)	6 (40)	3 (20)	3 (20)	15 (36.6)
Adenocarcinoma	2 (7.7)	7 (26.9)	9 (34.6)	8 (30.8)	26 (63.4)
Stage					
IIIA	1 (100)	-	-	-	1 (2.4)
IIIC	-			2 (100)	2 (4.9)
IV	4 (10.5)	13 (34.2)	12 (31.6)	9 (23.7)	38 (92.7)
ECOG PS					
0–1	5 (13.2)	11 (28.9)	12 (31.6)	10 (26.3)	38 (92.7)
2	-	2 (66.7)	-	1 (33.3)	3 (7.3)
PD-L1 (TPS)					
≥1%	-	4 (40)	4 (40)	2 (20)	10 (24.4)
<1%	1 (8.3)	4 (33.3)	2 (16.7)	5 (41.7)	12 (29.3)
Unknown	4 (21.0)	5 (26.3)	6 (31.6)	4 (21.0)	19 (46.3)
Genetic mutation					
EGFR	2 (14.3)	3 (21.4)	5 (35.7)	4 (28.6)	14 (34.1)
ALK	-	-	2	-	2 (4.9)
EGFR/ALK wild type	1 (6.25)	6 (37.5)	4 (25)	5 (31.25)	16 (39.0)
Unknown	2 (22.2)	4 (44.4)	1 (11.1)	2 (22.2)	9 (22.0)
Metastasis locations					
Liver	1 (7.7)	6 (46.2)	5 (38.5)	1 (7.7)	13 (31.7)
Brain	1 (5.9)	7 (41.2)	5 (29.4)	4 (23.5)	17 (41.5)
Bone	1 (4.8)	8 (38.1)	7 (33.3)	5 (23.8)	21 (51.2)
Adrenal glands	2 (28.6)	1 (14.3)	4 (57.1)	-	7 (17.1)
Treatment lines of cadonilimab					
2	-	1 (25)	3 (75)	-	4 (9.8)
≥ 3	5 (13.5)	12 (32.4)	12 (32.4)	8 (21.6)	37 (90.2)
≥ 4	5 (17.2)	10 (34.5)	10 (34.5)	4 (13.8)	29 (70.7)
Previous anti-PD-1/PD-L1 antibodies					
Yes	5 (13.2)	13 (34.2)	10 (26.3)	10 (26.3)	38 (92.7)
No	-	-	2 (66.7)	1 (33.3)	3 (7.3)
Response to cadonilimab (N = 23)					
PR	-	-	1 (100)	-	1 (4.3)
SD	2 (25)	2 (25)	2 (25)	2 (25)	8 (34.8)
PD	1 (7.1)	4 (28.6)	2 (14.3)	7 (50)	14 (60.9)

Abbreviations: ECOG PS, Eastern Cooperative Oncology Group Performance Status; PD-L1(TPS), programmed cell death ligand-1 (tumor proportion score); PD-1, programmed cell death-1; PR, partial response; SD, stable disease; PD, progressive disease.




FIGURE 2 Response of all evaluated patients to cadonilimab therapy. Cado + Chemo, cadonilimab + chemotherapy; Cado + Anlo, cadonilimab + anlotinib; Cado + OAA, cadonilimab + other antiangiogenic agents; Cado + AA, cadonilimab + antiangiogenic agents; DCR, disease control rate; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; NCAA, no combination of antiangiogenic agents; PD, progressive disease; PD-L1, programmed cell death-ligand 1; PR, partial response; SD, stable disease; WT, wild type.

received afatinib for 1 month and radiotherapy (77Gy/22f) simultaneously. Due to the low abundance of the EGFR 19del mutation, the multidisciplinary team believed that the benefit of targeted therapy might be limited and recommended consolidation immunotherapy. He began durvalumab consolidation on June 7, 2022, and the best response was stable disease. During durvalumab consolidation, the disease progressed on October 20, 2022, with thoracic CT showing pleural effusion on the left side, a mass in the hilus of left lung, and multiple pleural metastases. Thoracic puncture and pleural effusion drainage were performed on November 2, 2022, and intrapleural chemotherapy infusion was given with cisplatin and recombinant human endostatin. No EGFR mutation was detected in the pleural effusion. Cadonilimab and anlotinib were administered on November 19, 2022 with a best response of PR achieved (Figure 6).

Prognostic factors

Univariate and multivariate Cox proportional hazards models were used to identify prognostic factors affecting PFS in this previously heavily treated advanced NSCLC cohort (Table 2). Univariate analysis revealed that male gender and smoking history were related to favorable PFS ($p < 0.05$). Due to the high collinearity between gender and smoking history, a multivariate Cox proportional hazards model was not conducted.

Safety outcomes

TRAEs were observed in 26 patients (63.4%), with five patients (12.2%) experiencing grade 3 or higher TRAEs




FIGURE 3 Kaplan-Meier survival curves of (a) overall survival and (b) progression-free survival in all evaluated patients.




FIGURE 4 Kaplan-Meier survival curves of progression-free survival in all evaluated patients: (a) patients stratified according to PD-L1 expression status and (b) patients stratified according to the number of metastasis locations.




FIGURE 5 Kaplan-Meier survival curves of progression-free survival according to driver gene mutation types in all evaluated patients with squamous cell carcinoma and adenocarcinoma histological subtypes: (a) patients stratified according to histological subtypes; (b) patients stratified according to driver gene mutation types; and (c) patients categorized into two groups: adenocarcinoma without mutation and squamous carcinoma.

according to the CTCAE Version 5.0. The overall incidence rate of TRAEs was 43.8% among patients with *EGFR*/*ALK* mutations (Supplementary Table 1), which was not higher

than that in the overall patient population. The most frequently reported TRAEs were elevated gamma-glutamyl transferase (17.1%), cough (14.6%), and fatigue (12.2%). A




FIGURE 6 Imaging taken during cadonilimab treatment of the specific patient achieving partial response. anlo, anlotinib; cado, cadonilimab.

total of nine patients (22%) experienced irAEs, which included rash in four patients (9.8%), infusion reactions in two patients (4.9%), TSH elevation in one patient (2.4%), pruritus in one patient (2.4%), and myocarditis in one

patient (2.4%). The incidence of TRAEs resulting in drug discontinuation was 17.1%. Medications were discontinued in six patients due to adverse events, and in one patient due to cachexia. Specifically, two patients temporarily paused

TABLE 2 Univariate analysis and multivariate analysis of PFS in all NSCLC patients.

Factor	Univariate analysis		
	HR	95% CI	p value
Gender	0.245	0.081–0.735	0.012*
Male			
Female			
Age	0.318	0.041–2.433	0.270
>65			
≤65			
Smoking history	0.273	0.083–0.900	0.033*
Ever			
Never			
Histological type	0.328	0.091–1.184	0.089
Squamous cell carcinoma			
Adenocarcinoma			
ECOG PS	0.601	0.131–2.754	0.512
0–1			
2			
PD-L1 (TPS)	1.680	0.402–7.018	0.477
<1%			
≥1%			
EGFR/ALK mutation	2.958	0.920–9.506	0.069
Yes			
No			
Liver metastasis location	2.368	0.728–7.700	0.152
Yes			
No			
Brain metastasis location	1.943	0.676–5.583	0.218
Yes			
No			
Bone metastasis location	2.007	0.669–6.022	0.214
Yes			
No			
Metastasis location	1.951	0.640–5.943	0.240
≥2			
<2			
Combined with antiangiogenic agents	0.661	0.215–2.030	0.470
Yes			
No			
Combined with chemotherapy	1.528	0.474–4.924	0.477
Yes			
No			
Combined with anlotinib	0.522	0.116–2.355	0.398
Yes			
No			
Treatment lines	2.649	0.799–8.783	0.111
>3			
≤3			

Abbreviations: HR, hazard ratio; CI, confidence interval; BMI, body mass index; ECOG PS, Eastern Cooperative Oncology Group Performance Status; PD-L1, programmed cell death-ligand 1; EGFR/ALK, epidermal growth factor receptor/anaplastic lymphoma kinase.

their medication because of Grade 2 rash; one patient and two patients permanently discontinued due to Grade 3 ICI-related myocarditis and Grade 2 infusion reactions, respectively. It is noteworthy that the patient who discontinued cadonilimab due to dyspnea had a history of pericardial effusion and chronic obstructive pulmonary disease prior to the administration of cadonilimab. A comprehensive list of all safety outcomes is shown in Table 3.

DISCUSSION

To the best of our knowledge, this study represents the first real-world investigation into the efficacy and safety profile of cadonilimab in patients with advanced NSCLC. In this cohort, which had been heavily pretreated—92.7% of patients had progressed following anti-PD-1/PD-L1 therapy—cadonilimab-based regimens were administered as

TABLE 3 Safety summary: cadonilimab treatment-related adverse events.

Adverse events, N (%)	Mono therapy	With chemotherapy	With anlotinib	With other antiangiogenic agents	All (N = 41)
TRAEs					
All TRAEs	3 (11.5)	10 (38.5)	5 (19.2)	8 (30.8)	26 (63.4)
≥G3 TRAEs	1 (20)	2 (40)	-	2 (40)	5 (12.2)
GGT elevation	-	-	-	1 (100)	1 (2.4)
Thrombocytopenia	-	-	-	1 (100)	1 (2.4)
ICI-related myocarditis	-	1 (100)	-	-	1 (2.4)
Anemic	-	1 (100)	-	-	1 (2.4)
Dyspnea	1 (100)	-	-	-	1 (2.4)
Reported in ≥10% of patients					
GGT elevation	1 (14.3)	2 (28.6)	2 (28.6)	2 (28.6)	7 (17.1)
Cough	2 (33.3)	3 (50)	-	1 (16.7)	6 (14.6)
Fatigue	-	3 (60)	-	2 (40)	5 (12.2)
Immune-related adverse events					
All irAEs	-	4 (44.4)	-	5 (55.6)	9 (22)
Rash	-	2 (50)	-	2 (50)	4 (9.8)
Infusion reactions	-	1 (50)	-	1 (50)	2 (4.9)
TSH elevation	-	-	-	1 (100)	1 (2.4)
Pruritus	-	-	-	1 (100)	1 (2.4)
ICI-related myocarditis	-	1 (100)	-	-	1 (2.4)
≥G3 irAEs	-	-	-	-	1 (2.4)
ICI-related myocarditis	-	1 (100)	-	-	1 (2.4)
Leading to discontinuation	1 (14.3)	4 (57.1)	-	2 (28.6)	7 (17.1)
Caused by irAEs	-	3 (60)	-	2 (40)	5 (12.2)
Caused by cachexia	-	1 (100)	-	-	1 (2.4)
Caused by dyspnea	1 (100)	-	-	-	1 (2.4)

Abbreviations: G3, grade 3; GGT, gamma-glutamyl transferase; ICI-related myocarditis, immune checkpoint inhibitor-related myocarditis; irAEs, immune-related adverse events; TRAEs, treatment-related adverse events.

third-line or later treatment in the majority of cases (90.2%). These regimens exhibited moderate efficacy, with an ORR of 4.3% and a DCR of 39.1%. The safety profile was manageable, and the incidence of Grade 3 or higher TRAEs was 12.2%.

Over the past decade, ICIs have revolutionized the therapeutic landscape for solid tumors. Notably, several inhibitors targeting PD-1, PD-L1, and CTLA-4 have emerged, demonstrating promising efficacy and an acceptable safety profile across a variety of solid tumors. Among the various therapeutic strategies, the combination of two ICIs stands out as particularly promising, particularly the pairing of PD-1/PD-L1 inhibitors with CTLA-4 inhibitors. Mechanistically, CTLA-4 inhibits T cell activation during the antigen presentation phase, while PD-1/PD-L1 inhibitors act during the antigen elimination phase. This complementary action underpins the rationale for combining these agents.¹³ Pre-clinical data have demonstrated that the dual inhibition of CTLA-4 and PD-1/PD-L1 synergistically boosts T cell proliferation and suppresses Treg-mediated suppression of anti-tumor responses.^{14,15} Clinical trials corroborate that the synergistic inhibition of PD-1/PD-L1 and CTLA-4 pathways

yields favorable outcomes in urothelial carcinoma, NSCLC, and melanoma.¹⁶⁻¹⁸ Nivolumab in combination with ipilimumab has demonstrated efficacy and safety in treating advanced NSCLC in the CheckMate 012 trial.¹⁹ This immunotherapy combination has further demonstrated a significant survival benefit over standard chemotherapy in the subsequent CheckMate 227 trial, reinforcing its role as a valuable treatment option for this patient population.²⁰ In 2020, the combination of nivolumab and ipilimumab was approved as a first-line treatment option for patients with metastatic NSCLC (PD-L1 ≥1%) who lack sensitizing EGFR mutations or ALK translocations.

The effectiveness of this strategy for advanced NSCLC patients who have progressed on anti-PD-1/PD-L1 therapy is still uncertain, given that PD-1/PD-L1 inhibitor-based regimens have become the standard first-line treatment approach. A recent phase II trial, however, has shed light on the potential antitumor activity of the immunotherapy combination of durvalumab and tremelimumab in patients with metastatic NSCLC who are refractory to prior PD-L1 therapy.²¹ However, the efficacy of this combination was found to be limited in patients with metastatic squamous NSCLC,

as evidenced by the Lung-MAP S1400F study. In this study, patients who had progressed from anti-PD-L1 therapy within 24 weeks or more experienced an ORR of 0 and a median OS of 7.7 months.²² In our present study, a significant proportion of patients, 92.7%, had received PD-1 or PD-L1 inhibitors as first-line therapy. For 90.2% of these patients, cdonilimab-based regimen was administered as a third-line or later treatment. The observed ORR was 4.1%, and the DCR was 39.1%. The median PFS was 108 days, and the median OS was not reached at the time of analysis, likely due to the short follow-up period. Recently, a prospective study evaluated the efficacy and safety of cdonilimab in patients with previously treated NSCLC as a second-line therapy.²³ It showed an ORR of 10% and 0 in immunotherapy-naïve group and immunotherapy-resistant group, respectively. However, the sample size of immunotherapy-resistant group was only 23 in the above study. Exploration is needed into larger-scale clinical trials and potential beneficiary populations. The VEGF family is known to play a crucial role in tumor microenvironment remodeling. A previous study has reported the effectiveness of combining cdonilimab with the VEGF inhibitor anlotinib in the treatment of advanced NSCLC.¹² However, our study did not demonstrate superior efficacy for cdonilimab-based regimens that included antiangiogenic agents compared with those that did not (DCR of 35.7% vs. 44.4%, respectively).

Currently, there is a scarcity of studies aimed at identifying the specific patient populations that may derive the most benefit from PD-L1 and CTLA-4 bispecific antibodies. In the context of advanced NSCLC, where nivolumab combined with ipilimumab is used as a first-line therapy, the survival benefit observed has been consistent across various levels of PD-L1 expression.^{20,24} Our findings also indicated that PD-L1 expression level did not serve as a predictive factor for PFS or DCR following treatment with cdonilimab, which was in line with previous reports.²³ Our study revealed a trend suggesting that cdonilimab may exhibit a more pronounced antitumor effect in patients with advanced LUSC compared with those with LUAD, as evidenced by a higher DCR (70% vs. 15.4%) and longer PFS (129 vs. 57 days). This disparity might be attributed to the lower rate of driver gene mutations in LUSC. Indeed, we observed that patients with driver gene mutations had a shorter PFS than those with wild-type driver genes. Interestingly, no significant difference in PFS was noted between LUAD patients without driver gene mutations and those with LUSC. Further research is warranted to pinpoint molecular prognostic factors that can predict treatment response to cdonilimab in advanced NSCLC patients.

The simultaneous blockade of PD-1/PD-L1 and CTLA-4 using respective inhibitors has shown promising outcomes. However, this strategy is associated with a higher incidence of severe adverse events, and there is a lack of robust biomarkers to predict treatment response.^{13,17,18,25,26} In advanced solid tumors, the incidence rate of Grade 3 or higher TRAEs for combination immunotherapy with two ICIs has been reported to range from 27% to 53%.^{13,17,18,27}

Bispecific antibodies, which are designed to bind two distinct epitopes on the same or different antigens, have demonstrated the potential to enhance immune responses while aiming to minimize toxicity.^{26,28} In our study, the overall incidence rates of TRAEs and irAEs were 63.4% and 22%, respectively. The most frequently reported adverse events included elevated gamma-glutamyl transferase (17.1%), cough (14.6%), and fatigue (12.2%). Notably, only 12.2% of patients experienced Grade 3 or higher TRAEs, affecting five individuals. Based on these data, the bispecific antibody cdonilimab demonstrated a favorable safety profile compared with the combination therapy involving two ICIs.

This retrospective study had several inherent limitations. Firstly, the retrospective design of our study led to a lack of standardized matching in patient characteristics across different subgroups, potentially introducing selection bias. To mitigate this in future studies, we intend to enhance our research methodology by concentrating on well-defined subpopulations, ensuring that variables affecting patient survival are matched appropriately across groups. Secondly, the modest sample size of this real-world study might limit the statistical robustness of our findings. Consequently, the results, especially those derived from subgroup analyses, should be approached with caution. Thirdly, the median follow-up period was relatively brief. As of our data cutoff, a number of patients were still alive and had not yet experienced disease progression. We remain dedicated to ongoing follow-up efforts to assess the long-term survival outcomes for these individuals.

In summary, our findings indicate that cdonilimab-based regimens demonstrate moderate antitumor efficacy in heavily pretreated patients, including those who have received anti-PD-1 or anti-PD-L1 therapy. The safety profile of these regimens is deemed acceptable, with TRAEs generally being mild to moderate in severity and manageable. Nonetheless, further research is warranted to delve deeper into the efficacy of cdonilimab in the treatment of advanced NSCLC.

FUNDING INFORMATION

This work was supported by Shandong Provincial Natural Science Foundation (ZR2020LZL018), National Natural Science Foundation of China (82303749), Hui Lan Public Welfare Foundation Project (HLZY-20231128001), Beijing Science and Technology Innovation Medical Development Foundation (KC2023-JX-0186-PZ091), and Clinical Research Fund of Shandong Medical Association-Qilu Special Project (YXH2022ZX02212).

CONFLICT OF INTEREST STATEMENT

All authors declare that the research was conducted without any commercial or financial relationships and they have no conflict of interest.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

ORCID

Wen Zhao  <https://orcid.org/0000-0003-1077-4424>
 Chunyan Han  <https://orcid.org/0000-0002-0030-9839>
 Jun Wang  <https://orcid.org/0000-0003-3941-2507>
 Jisheng Li  <https://orcid.org/0000-0002-4186-6228>

REFERENCES

1. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48.
2. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83(5):584–94.
3. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26(21):3543–51.
4. Gadgeel S, Rodríguez-Abreu D, Speranza G, Esteban E, Felip E, Dómine M, et al. Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer. J Clin Oncol. 2020;38(14):1505–17.
5. Massari F, di Nunno V, Santoni M, Re: Arnaud Méjean, Alain Ravaud, Simon Thezenas, et al. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N Engl J Med. 2018;379:417–27: CAR-MENA trial: is this the end of cytoreductive nephrectomy in patients with clear-cell renal cell carcinoma? Eur Urol Oncol. 2019;2(3):340–1.
6. Lu S, Wu L, Jian H, Chen Y, Wang Q, Fang J, et al. Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): First interim results from a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2022;23(9):1167–79.
7. Rotte A. Combination of CTLA-4 and PD-1 blockers for treatment of cancer. J Exp Clin Cancer Res. 2019;38(1):255.
8. Motzer RJ, Tannir NM, McDermott D, Arén Frontera O, Melichar B, Choueiri TK, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378(14):1277–90.
9. Hellmann MD, Ciuleanu TE, Pluzanski A, Lee JS, Otterson GA, Audigier-Valette C, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med. 2018;378(22):2093–104.
10. Pang X, Huang Z, Zhong T, Zhang P, Wang ZM, Xia M, et al. Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity. MAbs. 2023;15(1):2180794.
11. Keam SJ. Cadonilimab: first approval. Drugs. 2022;82(12):1333–9.
12. Wu LJ, Chen B, Yao W, Li X, Xiao Z, Liu H, et al. 1300P a phase Ib/II trial of AK104 (PD-1/CTLA-4 bispecific antibody) in combination with anlotinib in advanced NSCLC. Ann Oncol. 2021;32:S1006.
13. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122–33.
14. Salama AK, Moschos SJ. Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies. Ann Oncol. 2017;28(1):57–74.
15. Chae YK, Arya A, Iams W, Cruz MR, Chandra S, Choi J, et al. Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC). J Immunother Cancer. 2018;6(1):39.
16. Gao J, Navai N, Alhalabi O, Siefker-Radtke A, Campbell MT, Tidwell RS, et al. Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat Med. 2020;26(12):1845–51.
17. Perets R, Bar J, Rasco DW, Ahn MJ, Yoh K, Kim DW, et al. Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer. Ann Oncol. 2021;32(3):395–403.
18. Olson DJ, Eroglu Z, Brockstein B, Poklepovic AS, Bajaj M, Babu S, et al. Pembrolizumab plus ipilimumab following anti-PD-1/L1 failure in melanoma. J Clin Oncol. 2021;39(24):2647–55.
19. Hellmann MD, Rizvi NA, Goldman JW, Gettinger SN, Borghaei H, Brahmer JR, et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol. 2017;18(1):31–41.
20. Paz-Ares LG, Ramalingam SS, Ciuleanu TE, Lee JS, Urban L, Caro RB, et al. First-line nivolumab plus ipilimumab in advanced NSCLC: 4-year outcomes from the randomized, open-label, phase 3 CheckMate 227 part 1 trial. J Thorac Oncol. 2022;17(2):289–308.
21. Schoenfeld JD, Giobbie-Hurder A, Ranasinghe S, Kao KZ, Lako A, Tsuji J, et al. Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 2022;23(2):279–91.
22. Leighl NB, Redman MW, Rizvi N, Hirsch FR, Mack PC, Schwartz LH, et al. Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (lung-MAP substudy S1400F, NCT03373760). J Immunother Cancer. 2021;9(8):e002973.
23. Zhao Y, Ma Y, Fan Y, Zhou J, Yang N, Yu Q, et al. A multicenter, open-label phase Ib/II study of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) monotherapy in previously treated advanced non-small-cell lung cancer (AK104-202 study). Lung Cancer. 2023;184:107355.
24. Reck M, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, et al. First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update. ESMO Open. 2021;6(5):100273.
25. O'Malley DM, Neff M, Monk BJ, Melkadem T, Huang M, Kryzhanivska A, et al. Dual PD-1 and CTLA-4 checkpoint blockade using Balstilimab and Zalifrelimab combination as second-line treatment for advanced cervical cancer: An open-label phase II study. J Clin Oncol. 2022;40(7):762–71.
26. Esfandiari A, Cassidy S, Webster RM. Bispecific antibodies in oncology. Nat Rev Drug Discov. 2022;21(6):411–2.
27. Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 2019;381(21):2020–31.
28. Burton EM, Tawbi HA. Bispecific antibodies to PD-1 and CTLA4: doubling down on T cells to decouple efficacy from toxicity. Cancer Discov. 2021;11(5):1008–10.

SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Li H, Zhao W, Li C, Shen H, Li M, Wang C, et al. The efficacy and safety of a novel PD-1/CTLA-4 bispecific antibody cadonilimab (AK104) in advanced non-small cell lung cancer: A multicenter retrospective observational study. Thorac Cancer. 2024;15(32):2327–38. <https://doi.org/10.1111/1759-7714.15455>